Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study on the Safety, Tolerability and Preliminary Efficacy of C019199 in Combination With Sintilimab in Patients With Advanced Solid Tumors

NCT06220318 is registered in ClinicalTrials.gov with Fujian Haixi Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06220318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06220318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study on the Safety, Tolerability and Preliminary Efficacy of C019199 in Combination With Sintilimab in Patients With Advanced Solid Tumors
Lead sponsor
Fujian Haixi Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 19, 2023
Completion date
August 30, 2026
Enrollment
155 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor